関節リウマチ検査装置の世界市場分析・予測

◆英語タイトル:MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts
◆商品コード:GDME0230MAR
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月11日
◆ページ数:149
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,995 ⇒換算¥683,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD11,990 ⇒換算¥1,366,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD17,985 ⇒換算¥2,050,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、関節リウマチ検査装置の世界市場について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・関節リウマチ検査装置産業概観
・アンメットニーズ分析
・関節リウマチ検査装置の市場機会分析
・市場の成長要因および阻害要因
・競争分析
・関節リウマチ検査装置の製品パイプライン分析
・関節リウマチ検査装置の治験動向
・主要企業分析
・関節リウマチ検査装置の世界市場規模予測
・関節リウマチ検査装置の地域別市場規模予測
【レポートの概要】

MediPoint: Rheumatoid Arthritis Testing – Global Analysis and Market Forecasts

Summary

Rheumatoid Arthritis (RA) is the commonest autoimmune disease in humans. The disease is prevalent in all ethnic groups, affecting approximately 1.0% of the world population. Presently there is a huge presence of unmet patient needs for both the treatment and diagnosis.

Focus for the treatment paradigm has now shifted towards the early detection and diagnosis of the disease, which will allow physicians to begin aggressive treatment of the condition, minimizing the associated complications and tissue damage.

Global sales of $347m in 2016 and estimated growth rate of 2% during the forecast period; the emerging markets: Brazil, Canada, China and Mexico are expected to show the fastest growth.

Key market drivers –
- Increasing prevalence of autoimmune diseases globally including RA
- Emerging biomarkers and advancement in technology for the early diagnosis of RA
- Increasing adoption of anti-cyclic citrullinated peptide (anti-CCP) antibody test
- Rising demand for lab automation

Key market barriers –
- Limited sensitivity of existing RA diagnostic tests
- Healthcare cost-cutting and reduced reimbursement in major markets

Highlights

Key Questions Answered

- What is the current and future RA testing market outlook in the developed and emerging markets? What trends are affecting the global market?
- What is the competitive landscape and who are major players in the RA testing space?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the RA tests currently on the market? How will emerging technologies such as POC assays fulfil these unmet needs?
- What are the key products and pipelines in the RA testing market?
- What are the challenges and barriers that have hindered widespread adoption of RA tests in different regions?

Scope

- Competitive assessment: Currently marketed RA diagnostic products and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different RA diagnostic tests
- Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Pipeline analysis: Emerging products and technologies.
- Annualized total RA testing market revenue by segment and market outlooks by country from 2013-2022.
- Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track device sales in the global market from 2012-2021
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

【レポートの目次】

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 17
3 Market Access 18
3.1 Rheumatoid Arthritis Testing Overview 18
3.2 Reimbursement Trends 20
3.2.1 North America 20
3.2.2 Europe 23
3.2.3 Asia-Pacific 24
3.2.4 South America 26
3.3 Mergers, Acquisitions, and Key Partnerships 28
4 Unmet Needs 29
4.1 Earlier Diagnosis 29
4.2 Seronegativity and Sensitivity 29
4.2.1 Rheumatoid Factor 29
4.2.2 Anti-Cyclic Citrullinated Peptide Antibody 30
4.2.3 14-3-3η 30
4.3 Novel Biomarkers for Rheumatoid Arthritis Diagnosis 31
5 Competitive Assessment 32
5.1 Company Share Analysis 32
5.1.1 Global 32
5.2 Abbott Diagnostics 33
5.2.1 Overview 33
5.2.2 Marketed Products Assessment 34
5.2.3 SWOT Analysis 35
5.3 Beckman Coulter 35
5.3.1 Overview 35
5.3.2 Marketed Products Assessment 36
5.3.3 Pipeline Products Assessment 37
5.3.4 SWOT Analysis 38
5.4 Bio-Rad Laboratories 39
5.4.1 Overview 39
5.4.2 Marketed Products Assessment 39
5.4.3 SWOT Analysis 40
5.5 Euro-Diagnostica 41
5.5.1 Overview 41
5.5.2 Marketed Products Assessment 41
5.5.3 SWOT Analysis 43
5.6 Inova Diagnostics 43
5.6.1 Overview 43
5.6.2 Marketed Products Assessment 44
5.6.3 SWOT Analysis 45
5.7 Quest Diagnostics 45
5.7.1 Overview 45
5.7.2 Marketed Products Assessment 46
5.7.3 SWOT Analysis 48
5.8 F. Hoffmann-La Roche 48
5.8.1 Overview 48
5.8.2 Marketed Products Assessment 49
5.8.3 SWOT Analysis 50
5.9 Siemens Healthcare 50
5.9.1 Overview 50
5.9.2 Marketed Products Assessment 51
5.9.3 Pipeline Products Assessment 52
5.9.4 SWOT Analysis 53
5.10 SQI Diagnostics 53
5.10.1 Overview 53
5.10.2 Marked Products Assessment 54
5.10.3 SWOT Analysis 55
5.11 Thermo Fisher Scientific 55
5.11.1 Overview 55
5.11.2 Marketed Products Assessment 56
5.11.3 Pipeline Products Assessment 57
5.11.4 SWOT Analysis 58
5.12 Other Companies 59
6 Market Outlook 63
6.1 Test Trends 63
6.1.1 Rheumatoid Factor Testing 63
6.1.2 Anti-Cyclic Citrullinated Peptide Antibody Testing 67
6.1.3 C-Reactive Protein Testing 71
6.2 Market Dynamics 74
6.2.1 Driver: Increasing Anti-CCP Antibody Testing 74
6.2.2 Driver: Innovative Tests for Rheumatoid Arthritis 74
6.2.3 Driver: Rising Demand for Lab Automation 75
6.2.4 Driver: Rising Prevalence of Rheumatoid Arthritis 76
6.2.5 Barrier: Limited Sensitivity of Existing Tests 76
6.2.6 Barrier: Healthcare Cost-Cutting 77
6.2.7 Barrier: Medical Device Excise Tax 77
6.3 Market Outlooks by Segment 78
6.3.1 Global Overview 78
6.3.2 Rheumatoid Factor Tests 83
6.3.3 Anti-Cyclic Citrullinated Peptide Antibody Tests 85
6.3.4 C-Reactive Protein Tests 86
6.4 Market Outlooks by Geography 88
6.4.1 Global Overview 88
6.4.2 US 92
6.4.3 France 95
6.4.4 Germany 98
6.4.5 Italy 100
6.4.6 Spain 103
6.4.7 UK 106
6.4.8 Japan 110
6.4.9 Australia 113
6.4.10 Brazil 116
6.4.11 Canada 119
6.4.12 China 121
6.4.13 India 124
6.4.14 Mexico 127
6.4.15 Russia 129
6.4.16 South Korea 131
7 Appendix 134
7.1 Bibliography 134
7.2 Abbreviations 139
7.3 Report Methodology 142
7.3.1 Overview 142
7.3.2 Coverage 142
7.3.3 Secondary Research 142
7.3.4 Forecasting Methodology 143
7.3.5 Primary Research – Key Opinion Leader Interviews 144
7.3.6 Primary Research – Physician and Industry Interviews 145
7.3.7 Expert Panel Validation 146
7.4 About the Team 146
7.4.1 Analysts 146
7.4.2 David Brady, Director of Operations – Market Research 147
7.4.3 Tyler Fletcher, Global Head of Medical Devices 147
7.5 About MediPoint 148
7.6 About GlobalData 148
7.7 Disclaimer 148

1.1 List of Tables
Table 1: Rheumatoid Arthritis Classification Criteria 19
Table 2: Medicare National Average of Clinical Laboratory Services Reimbursement for Rheumatoid Arthritis Testing, 2014-2015 22
Table 3: Mergers, Acquisitions, and Key Partnerships, 2014-2016 28
Table 4: Company Profile - Abbott Diagnostics 34
Table 5: Abbott Diagnostics’ RA Testing Portfolio Assessment, 2016 34
Table 6: SWOT Analysis - Abbott Diagnostics 35
Table 7: Company Profile - Beckman Coulter 36
Table 8: Beckman Coulter’s RA Testing Portfolio Assessment, 2016 36
Table 9: Beckman Coulter’s RA Testing Pipeline, 2016 37
Table 10: SWOT Analysis - Beckman Coulter 38
Table 11: Company Profile - Bio-Rad Laboratories 39
Table 12: Bio-Rad Laboratories’ RA Testing Portfolio Assessment, 2016 40
Table 13: SWOT Analysis - Bio-Rad Laboratories 40
Table 14: Company Profile - Euro-Diagnostica 41
Table 15: Euro-Diagnostica’s RA Testing Portfolio Assessment, 2016 42
Table 16: SWOT Analysis - Euro-Diagnostica 43
Table 17: Company Profile - Inova Diagnostics 44
Table 18: Inova Diagnostics’ RA Testing Portfolio Assessment, 2016 44
Table 19: SWOT Analysis - Inova Diagnostics 45
Table 20: Company Profile - Quest Diagnostics 46
Table 21: Quest Diagnostics’ RA Testing Portfolio Assessment, 2016 47
Table 22: SWOT Analysis - Quest Diagnostics 48
Table 23: Company Profile - F. Hoffmann-La Roche 49
Table 24: F. Hoffmann-La Roche’s RA Testing Portfolio Assessment, 2016 49
Table 25: SWOT Analysis - F. Hoffmann-La Roche 50
Table 26: Company Profile - Siemens Healthcare 51
Table 27: Siemens Healthcare’s RA Testing Portfolio Assessment, 2016 52
Table 28: Siemens Healthcare’s RA Testing Pipeline, 2016 52
Table 29: SWOT Analysis - Siemens Healthcare 53
Table 30: Company Profile - SQI Diagnostics 54
Table 31: SQI Diagnostics’ RA Testing Portfolio Assessment, 2016 54
Table 32: SWOT Analysis - SQI Diagnostics 55
Table 33: Company Profile - Thermo Fisher Scientific 56
Table 34: Thermo Fisher Scientific’s RA Testing Portfolio Assessment, 2016 56
Table 35: Thermo Fisher Scientific’s RA Testing Pipeline, 2016 57
Table 36: SWOT Analysis - Thermo Fisher Scientific 58
Table 37: Other Companies Involved in the Rheumatoid Arthritis Testing Market, 2016 59
Table 38: Global RF Test Volume Forecast (thousands) by Country, 2013-2022 64
Table 39: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022 68
Table 40: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022 71
Table 41: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 79
Table 42: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022 84
Table 43: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022 85
Table 44: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022 87
Table 45: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Country, 2013-2022 89
Table 46: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 93
Table 47: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 96
Table 48: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 99
Table 49: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 101
Table 50: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 104
Table 51: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 107
Table 52: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 110
Table 53: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 113
Table 54: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 117
Table 55: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 119
Table 56: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 122
Table 57: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 125
Table 58: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 128
Table 59: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 130
Table 60: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 132
Table 61: Rheumatoid Arthritis Testing - Primary Call Count by Country 145

1.2 List of Figures
Figure 1: Global RA Testing Market, By Company Share, 2015 33
Figure 2: Global RF Test Volume Forecast (thousands) by Country, 2013-2022 65
Figure 3: Global RF Test Volume Share Forecast (%) by Country, 2015 and 2022 66
Figure 4: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022 69
Figure 5: Global Anti-CCP Antibody Test Volume Share Forecast (%) by Country, 2015 and 2022 70
Figure 6: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022 72
Figure 7: Global CRP Test Volume Share Forecast (%) by Country, 2015 and 2022 73
Figure 8: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 80
Figure 9: Global Rheumatoid Arthritis Analyzer Test Market Share Forecast (%) by Test, 2015 and 2022 81
Figure 10: Global Rheumatoid Arthritis Manual Test Market Share Forecast (%) by Test, 2015 and 2022 82
Figure 11: Global Rheumatoid Arthritis Testing Market Potential by Test, 2022 83
Figure 12: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022 84
Figure 13: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022 86
Figure 14: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022 87
Figure 15: Global Rheumatoid Arthritis Testing Sales Forecast ($m), 2013-2022 90
Figure 16: Global Rheumatoid Arthritis Testing Market Share Forecast (%) by Country, 2015 and 2022 91
Figure 17: Global Rheumatoid Arthritis Testing Market Potential by Country, 2022 92
Figure 18: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 94
Figure 19: US Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 95
Figure 20: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 97
Figure 21: France Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 98
Figure 22: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 99
Figure 23: Germany Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 100
Figure 24: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 102
Figure 25: Italy Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 103
Figure 26: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 105
Figure 27: Spain Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 106
Figure 28: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 108
Figure 29: UK Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 109
Figure 30: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 111
Figure 31: Japan Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 112
Figure 32: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 114
Figure 33: Australia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 115
Figure 34: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 117
Figure 35: Brazil Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 118
Figure 36: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 120
Figure 37: Canada Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 121
Figure 38: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 123
Figure 39: China Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 124
Figure 40: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 126
Figure 41: India Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 127
Figure 42: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 128
Figure 43: Mexico Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 129
Figure 44: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 130
Figure 45: Russia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 131
Figure 46: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022 132
Figure 47: South Korea Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022 133
Figure 48: Rheumatoid Arthritis Testing - Primary Call Count by Country (N=75) 145

【掲載企業】

Abbott Diagnostics
Beckman Coulter
Bio-Rad Laboratories
Euro-Diagnostica
Inova Diagnostics
Quest Diagnostics
F. Hoffmann-La Roche
Siemens Healthcare
SQI Diagnostics
Thermo Fisher Scientific

【レポートのキーワード】

関節リウマチ検査装置

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[関節リウマチ検査装置の世界市場分析・予測]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月10日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆